• Cannabidiol in Orofacial Inflammatory Pain: Study Analysis

  2026-08-22

  This 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce inflammatory pain while also improving affective and cognitive abnormalities in mouse models. Its central innovation is a multi-level analysis linking peripheral cannabinoid signaling, trigeminal and cortical neuronal activity, endocannabinoid changes, and serotonin dynamics in the central amygdala.

• Viral RIPK3 Degradation and Inflammation

  2026-08-21

  The Immunity study identified a conserved orthopoxvirus factor, vIRD, that recruits SCF machinery to ubiquitinate and degrade RIPK3, suppressing necroptosis while enhancing viral fitness. Its genetic and infection-model evidence shows that viral manipulation of host protein degradation can simultaneously shape inflammation, replication, and disease severity.

• Fluoxetine HCl: Reproducible Cell Assays

  2026-08-21

  Learn how Fluoxetine HCl (SKU A2436) can support reproducible cell-based studies of serotonergic signaling, receptor function, proliferation, and viability. This scenario-driven guide distinguishes pathway activity from cytotoxicity and provides practical handling, concentration-selection, interpretation, and vendor-evaluation guidance.

• Ziprasidone Augmentation in Anxious Depression

  2026-08-20

  This post-hoc moderator analysis examined whether baseline anxious depression changed the response to ziprasidone added to escitalopram in patients with major depressive disorder. Depression improvement did not differ significantly between anxiety subgroups, while the numerical anxiety benefit in more anxious patients was small and not clinically meaningful, emphasizing the need to separate symptom-domain effects in antidepressant research.

• Quercetin: From PI3K Signals to NLRP3 Evidence

  2026-08-20

  Quercetin is a context-dependent PI3K inhibitor and anti-inflammatory agent whose effects extend from mitochondrial apoptosis to microglial inflammasome signaling. This article presents an evidence-layered strategy for interpreting quercetin experiments across cancer research and neuroinflammation without confusing pathway convergence with target specificity.

• Tropisetron Hydrochloride: Applied Workflows

  2026-08-19

  Tropisetron Hydrochloride supports a paired strategy for studying 5-HT3 receptor signaling, α7-nicotinic receptor activity, and renal organic-cation transport. This guide translates its dual pharmacology into practical receptor, OCT2, MATE1, and transcellular assay workflows with troubleshooting guidance.

• Sumatriptan: From Receptor Probe to Assay Design

  2026-08-19

  Sumatriptan Succinate is more than a migraine research compound: it is a context-sensitive 5-HT1 receptor agonist whose metabolites can reshape assay interpretation. This guide connects receptor pharmacology, neurogenic inflammation, and the updated CYP–MAO metabolism evidence to practical experimental design.

• Reversine: Aurora Kinase Inhibitor Workflow Guide

  2026-08-18

  Reversine (SKU A3760) provides a dossier-defined Aurora kinase inhibitor for controlled studies of mitotic regulation, cell-cycle behavior, cancer cell proliferation inhibition, and apoptosis-related endpoints. This guide covers preparation, assay planning, and quality control; the compound is for scientific research only and should not be used for diagnosis, treatment, or other clinical purposes.

• WAY-100635: A Translational 5-HT1A Lens

  2026-08-18

  WAY-100635 gives translational researchers a selective, mechanistically clean way to test whether 5-HT1A signaling contributes to pain, affective dysfunction, and serotonergic circuit activity. This article connects receptor pharmacology with the 2026 cannabidiol study on orofacial inflammatory pain and outlines how to move from binding assays to behavioral and imaging hypotheses.

• NMDA: Designing Glaucoma Excitotoxicity Assays

  2026-08-17

  NMDA (N-Methyl-D-aspartic acid) can do more than induce neuronal injury: it can help connect receptor-driven calcium loading with oxidative stress and ferroptosis phenotypes. This guide translates a retinal glaucoma study into a tiered, decision-focused assay strategy.

• Chicken GSDME Drives RNA Virus-Induced Pyroptosis

  2026-08-17

  Chen et al. identify chicken GSDME as a major pore-forming effector of RNA virus-induced pyroptosis, resolving a long-standing question created by the absence of GSDMD in chickens. Using viral infection, Poly(I:C) stimulation, pathway analysis, and chGSDME loss-of-function models, the study connects MDA5–caspase signaling to pyroptosis and viral release in chicken cells.

• Low-Dose Cadmium, STAT3, and Lymphangiogenesis

  2026-08-16

  The reference study identifies STAT3 activation as a signaling link between low-dose cadmium exposure and enhanced lymphatic vessel growth after corneal injury. Its combination of an in vivo alkali-burn model, lymphatic endothelial cell assays, pathway profiling, and STAT3 inhibition supports a cadmium–STAT3–VEGFR3 mechanism while also revealing dose-dependent effects.

• Brassinolide: Mechanism, Evidence, and Workflows

  2026-08-15

  Brassinolide, also called 24-Epibrassinolide, is a plant steroid regulator with documented roles in plant development and research-reported effects in PC-3 prostate cancer cells and diabetic rat models. The evidence supports controlled use in plant bioassays, apoptosis studies, and metabolic research, but does not establish clinical efficacy.

• PDK4 Inhibitors: Mechanism, Models, and Translational Value

  2026-08-14

  The reference study used anthraquinone hit optimization to discover allosteric pyruvate dehydrogenase kinase 4 inhibitors, identifying compound 8c as a lead with biochemical, metabolic, allergic-disease, and anticancer activity. Its integrated potency, stability, pharmacokinetic, animal-model, cellular, and docking data provide a useful framework for assessing whether PDK4 inhibition can support broader metabolic-disease drug development.

• Zolmitriptan: From 5-HT1B Signaling to Translational Assays

  2026-08-14

  Zolmitriptan provides a defined pharmacological entry point for migraine and cluster headache research. This thought-leadership guide connects 5-HT receptor assay design with an evidence-bounded framework for exploring lysosomal biology without overstating an unproven cross-domain mechanism.

7910 records 3/528 page Previous Next 12345 下5页 Last page